A Microbot Medical Inc. investor won’t be able to take his defense against short-swing trading claims to the US Supreme Court ...

April 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the addition of two senior officers that ...

H.C. Wainwright's valuation of Microbot Medical stands at an estimated market value of $255 million, or $9 per share, which underpins the revised price target. The current market capitalization of ...

HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data ...

Jan. 14, 2021 (GLOBE NEWSWIRE) -- The continued progression of Microbot Medical Inc.’s (Nasdaq: MBOT) LIBERTY™ Robotic System was further demonstrated as the Company announced the successful ...

HINGHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering priced at-the-market ...

HINGHAM, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY ® Robotic System, the first single-use endovascular robotic system ...

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm ...